Table 1. The baseline characteristics of the serum survivin-2B measurements using ELISA in RA patients.
| Survivin-2B high (≥12 ng/ml) | Survivin-2B low (<12 ng/ml) | p-value | |
|---|---|---|---|
| (n = 18) | (n = 21) | ||
| Age | 68.9 ± 14.3 | 66.6 ± 9.7 | 0.553* |
| Sex (Female/Male) | F 17/M 1 | F 19/M 2 | 0.643† |
| Duration of RA (year) | 10.8 ± 9.2 | 12.6 ± 9.9 | 0.560* |
| Dose of glucocorticoids (prednisolone, mg/day) | 3.2 ± 2.1 | 3.2 ± 2.9 | 0.973* |
| Current use of non-biologic DMARDs | 15 (83.3%) | 20 (95.2%) | 0.246†,‡ |
| Current use of biologics | 7 (38.9%) | 7 (33.3%) | 0.718†,§ |
| Disease activity score of RA (DAS28-ESR) | 4.64 ± 1.10 | 3.64 ± 1.67 | 0.037** |
Mean ± Standard Deviation (SD).
DMARDs, disease modifying anti-rheumatic drugs.
*t-test, * p < 0.05.
†chi-square test.
‡Non-biologic DMARDs included methotrexate, tacrolimus, salazosulfapyridine, leflunomide, D-penicillamine, bucillamine.
§Biologics included etanercept, infliximab, golimumab, abatacept and tocilizumab.